Stock Events

Stock Events

Cue Biopharma 

$25.27
47
-$8.93-26.11% 15:43 Today

Statistics

Day High
27.95
Day Low
24.39
52W High
36.78
52W Low
5.31
Volume
140,769
Avg. Volume
141,332
Mkt Cap
106.14M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-24.14
-16.12
-8.09
-0.07
Expected EPS
-1.42
Actual EPS
N/A

Financials

-96.85%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
27.47MRevenue
-26.6MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CUE. It's not an investment recommendation.
Microsoft
9
MSFT
Amazon
9
AMZN
Apple
8
AAPL
Tesla
8
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, Inc. has a broad portfolio in oncology, including cell therapies, directly competing with Cue Biopharma's cancer immunotherapies.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb Company offers immunotherapy treatments for cancer, competing with Cue Biopharma's approach to engage specific immune responses.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is known for its checkpoint inhibitors and cancer immunotherapies, competing in the same space as Cue Biopharma.
Novartis
NVS
Mkt Cap286.78B
Novartis AG has a strong focus on research and development in immuno-oncology, making it a direct competitor in developing innovative cancer treatments.
AMGEN
AMGN
Mkt Cap224.63B
Amgen Inc. works on novel therapeutics in oncology and inflammation, areas that Cue Biopharma is also targeting with its biologics.
Allogene Therapeutics
ALLO
Mkt Cap708.26M
Allogene Therapeutics, Inc. is pioneering allogeneic CAR T-cell therapies, which compete with Cue Biopharma's efforts in cancer immunotherapy.

About

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Show more...
CEO
Shao-Lee Lin
Employees
29
Country
United States
ISIN
US22978P2056
WKN
000A426PN

Listings

F
DE
1UC0.F
MU
DE
1UC0.MU
XNAS
US
CUE
STU
DE
1UC0.STU

0 Comments

Share your thoughts

FAQ

What is Cue Biopharma stock price today?▼
The current price of CUE is $25.27 USD — it has decreased by -26.11% in the past 24 hours. Watch Cue Biopharma stock price performance more closely on the chart.
What is Cue Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cue Biopharma stocks are traded under the ticker CUE.
Is Cue Biopharma stock price growing?▼
CUE stock has fallen by -10.52% compared to the previous week, the month change is a -18.9% fall, over the last year Cue Biopharma has showed a +2.85% increase.
What is Cue Biopharma market cap?▼
Today Cue Biopharma has the market capitalization of 106.14M
When is the next Cue Biopharma earnings date?▼
Cue Biopharma is going to release the next earnings report on November 12, 2026.
What were Cue Biopharma earnings last quarter?▼
CUE earnings for the last quarter are -24.14 USD per share, whereas the estimation was -1.69 USD resulting in a -1,328.4% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cue Biopharma revenue for the last year?▼
Cue Biopharma revenue for the last year amounts to 27.47M USD.
What is Cue Biopharma net income for the last year?▼
CUE net income for the last year is -26.6M USD.
How many employees does Cue Biopharma have?▼
As of August 18, 2026, the company has 29 employees.
In which sector is Cue Biopharma located?▼
Cue Biopharma operates in the Health & Wellness sector.
When did Cue Biopharma complete a stock split?▼
The last stock split for Cue Biopharma was on April 24, 2026 with a ratio of 1:30.
Where is Cue Biopharma headquartered?▼
Cue Biopharma is headquartered in BOSTON, United States.